Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

RARE PHOTOS: 48 | Rare Historical Photos

Which of These 3 Medical Stocks Has the Better Growth Opportunities?

The medical sector is expected to grow amid steady demand and technological advancements. So, let's analyze which of these stocks, CVS Health (CVS), Walgreens Boots Alliance (WBA), and TRxADE HEALTH (MEDS), has the better growth opportunities.

StockNews.com

Supreme Court Halts Purdue Pharma’s $6B Settlement From A Challenge In A Lawsuit

The Supreme Court temporarily blocked a bankruptcy settlement by Purdue Pharma that would shield victims from civil lawsuits.

Zenger

Family of Henrietta Lacks files new lawsuit over cells harvested without her consent

The family of Henrietta Lacks has filed another lawsuit accusing a second company of unjustly profiting off her cells for generations

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Canopy Growth (CGC) vs. Collegium Pharmaceutical (COLL): Which Pharma Stock Is the Better Buy for Growth Investors?

The pharma industry is poised for long-term growth supported by increasing demand for drugs worldwide and technological advancements. While leading pharma stocks Collegium Pharmaceutical (COLL) and Canopy Growth (CGC) should benefit from the industry tailwinds, let us determine which is the better buy.

StockNews.com

Painkiller on Netflix review: this drama exploring America’s opioid crisis feels achingly real

This show skilfully captures the impossible emotional complexity of loving an addict

Evening Standard

An illicit, Chinese-owned lab fueled conspiracy theories. But officials say it posed no danger

The discovery of an illegal medical lab in central California by a code enforcement officer has unleashed an uproar in a rural community and fed anti-Chinese rumors online

The Independent UK

Should Value Investors Go After Pfizer (PFE)?

Pfizer Inc (PFE), currently trading at a discount, is charting a path to enduring expansion via strategic acquisitions and the introduction of novel products. Despite this drive, recent financial results lack significant optimism. Given this scenario, should investors invest in PFE? Let’s look at its financial metrics to gauge its…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Mexico shutters 23 pharmacies at Caribbean coast resorts after US warned of dangerous pill sales

Mexico has closed 23 pharmacies at Caribbean coast resorts, six months after a research report warned that drug stores in Mexico were offering foreigners pills they passed off as Oxycodone, Percocet, and Adderall

The Independent UK

3 Pharma Stocks Investors Are Chasing for Value

With the advent of advanced medications and the increasing need for personalized treatments, the pharmaceutical industry looks well-poised for long-term growth. Therefore, it could be worth looking into three fundamentally sound pharma stocks, Pfizer (PFE), Sanofi (SNY), and GSK plc (GSK), that are offering significant value. Read more….

StockNews.com

WHO medical product alert: one batch of Indian-made combination syrup found contaminated in Iraq

WHO warns of substandard COLD OUT syrup containing unacceptable amounts of diethylene glycol and ethylene glycol. The product may have been distributed to other countries and can be fatal if consumed. Increased vigilance and testing is recommended, as well as informing WHO if the substandard product is discovered.

The Hindu

3 Pharma Stock Buys You Don’t Want to Miss

The pharmaceutical industry is growing amid robust demand. Also, given that healthcare stocks are generally thought of as defensive investments, fundamentally strong Johnson & Johnson (JNJ), Novo Nordisk (NVO), and AstraZeneca (AZN) might be profitable buys now. Read on.

StockNews.com

Concord Biotech IPO: All you need to know

NEW DELHI: Concord Biotech, backed by Rare Enterprises, has announced the price band for its initial public offering (IPO) at Rs 705-741 per share, aiming to raise Rs 1,550 crore.

The Times of India

Study suggests how HIV drug formulation help improve treatment results for children worldwide

Researchers at the University of Colorado Anschutz Medical Campus have helped confirm the dose, safety, and efficacy of a drug formulation designed to treat children infected with the human immunodeficiency virus (HIV). Read further on Dynamite News:

Dynamite News

3 Biotech Stocks Smart Money Is After

Biotech companies such as Biogen (BIIB), Cidara Therapeutics (CDTX), and Theratechnologies (THTX) with the interest of institutional investors could be worth investing in now. Continue reading….

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Let's Talk About Walgreens Boots Alliance (WBA): Buy, Sell, or Hold?

Walgreens Boots Alliance (WBA) is attempting to raise capital and regain market share. Given this scenario, should investors buy, sell, or hold the stock? Let’s look at its financial metrics to gauge its prospects….

StockNews.com

3 Biotech Stocks With Strong Value in August

The biotech industry is ascending with growing R&D initiatives, an upsurge in personalized medicine, and enhanced drug formulations, coupled with the incorporation of technological advancements. So, it seems wise to invest in discounted biotech stocks Vertex Pharmaceuticals (VRTX), Jazz Pharmaceuticals (JAZZ), and Alkermes (ALKS) this month. Keep reading….

StockNews.com

Are Pfizer (PFE) and AbbVie (ABBV) Good Value Buys for August?

The pharma industry is poised to witness long-term growth with the introduction of generic medicines and growing demand for personalized and targeted treatments. Hence, fundamentally strong pharma stock AbbVie (ABBV) might be worth buying. However, it might not be the right time to invest in Pfizer (PFE). Keep reading.

StockNews.com

2 Must-Have Pharma Stocks to Buy in August, 1 to Sell

The pharmaceutical industry is poised to thrive amid increasing global healthcare demand. Hence, two quality pharma stocks, Johnson & Johnson (JNJ) and Novartis AG (NVS), could be solid portfolio additions. However, avoiding fundamentally weak stock SNDL Inc. (SNDL) could be a wise choice. Read more.

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Which is the Better Value Stock for August: Catalyst Pharmaceuticals, Inc. (CPRX) vs. Teva Pharmaceutical Industries (TEVA)?

Fueled by steady demand, the pharmaceutical sector has shown resilience and expansion even in an uncertain economic environment. Amid this scenario, Catalyst Pharmaceuticals (CPRX) and Teva Pharmaceuticals (TEVA) are set to reap the rewards. However, which of the two is the better value stock for August? Read more to find…

StockNews.com

Are These Biotech Stocks a Buy or Sell for August: Bionano Genomics (BNGO) vs. Cidara Therapeutics (CDTX)?

Underpinned by undeniable growth trends of an aging population, breakthrough therapies, and the inelastic demand for healthcare products and medicines, the biotech industry is expected to perform well in the near term. Given this backdrop, let’s compare two biotech stocks, Bionano Genomics (BNGO) and Cidara Therapeutics (CDTX), to determine if…

StockNews.com

Is Johnson & Johnson (JNJ) a Must-Buy Stability Stock?

Thanks to the company’s solid first-quarter performance and growing pharmaceutical demand, Johnson & Johnson’s (JNJ) long-term prospects look bright. However, could the company ensure stability for investors amid the current market volatility? Keep reading….

The Independent UK

Dangerous diseases found in illegal California medical lab with nearly 1,000 bioengineered mice

Police are still investigating the lab’s origins

The Independent UK

Biotech company settles lawsuit for profiting off of woman’s cloned cells for seven decades

Henrietta Lacks’ unique ‘Hela’ cells played a crucial role in the development of Covid-19 vaccines and treatments for HIV, leukemia and cancer

The Independent UK

Brain fog and other long COVID symptoms are the focus of new small treatment studies

The National Institutes of Health is starting some studies to test possible treatments for long COVID

Zenger

Centene Corporation’s Profits Heavily In Healthcare On Their Second Quarter Profits

The company reported a quarterly revenue of $33.71 billion and a net profit of $1.06 billion in their latest earnings release

1 … 47 48 49 50

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.